Tobradex St is a drug owned by Harrow Eye Llc. It is protected by 3 US drug patents filed from 2013 to 2016 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Aug 03, 2028. Details of Tobradex St's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US7795316 | Topical ophthalmic compositions containing tobramycin and dexamethasone |
Aug, 2028
(3 years from now) | Active |
| US8101582 | Topical ophthalmic compositions containing tobramycin and dexamethasone |
Dec, 2027
(3 years from now) | Active |
| US8450287 | Topical ophthalmic compositions containing tobramycin and dexamethasone |
Dec, 2027
(3 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Tobradex St's patents.
Latest Legal Activities on Tobradex St's Patents
Given below is the list of recent legal activities going on the following patents of Tobradex St.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Yr, Small Entity | 09 Jun, 2024 | US8450287 |
| Email Notification Critical | 12 Dec, 2023 | US8450287 |
| Change in Power of Attorney (May Include Associate POA) Critical | 12 Dec, 2023 | US8101582 |
| Email Notification Critical | 12 Dec, 2023 | US7795316 |
| Change in Power of Attorney (May Include Associate POA) Critical | 12 Dec, 2023 | US8450287 |
| Email Notification Critical | 12 Dec, 2023 | US8101582 |
| Change in Power of Attorney (May Include Associate POA) Critical | 12 Dec, 2023 | US7795316 |
| Payment of Maintenance Fee, 12th Yr, Small Entity | 24 Jan, 2023 | US8101582 |
| Payment of Maintenance Fee, 12th Yr, Small Entity | 14 Sep, 2021 | US7795316 |
| Payment of Maintenance Fee, 8th Yr, Small Entity | 12 Aug, 2020 | US8450287 |
US patents provide insights into the exclusivity only within the United States, but Tobradex St is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Tobradex St's family patents as well as insights into ongoing legal events on those patents.
Tobradex St's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Tobradex St's generic launch date based on the expiry of its last outstanding patent is estimated to be Aug 03, 2028 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Tobradex St Generic API suppliers:
Dexamethasone; Tobramycin is the generic name for the brand Tobradex St. 3 different companies have already filed for the generic of Tobradex St, with Amneal having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Tobradex St's generic
About Tobradex St
Tobradex St is a drug owned by Harrow Eye Llc. It is used for treating ocular inflammation with infection or risk of infection using a combination of tobramycin and dexamethasone. Tobradex St uses Dexamethasone; Tobramycin as an active ingredient. Tobradex St was launched by Harrow Eye in 2009.
Approval Date:
Tobradex St was approved by FDA for market use on 13 February, 2009.
Active Ingredient:
Tobradex St uses Dexamethasone; Tobramycin as the active ingredient. Check out other Drugs and Companies using Dexamethasone; Tobramycin ingredient
Treatment:
Tobradex St is used for treating ocular inflammation with infection or risk of infection using a combination of tobramycin and dexamethasone.
Dosage:
Tobradex St is available in suspension/drops form for ophthalmic use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 0.05%;0.3% | SUSPENSION/DROPS | Prescription | OPHTHALMIC |